ATE288268T1 - Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethoden - Google Patents
Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethodenInfo
- Publication number
- ATE288268T1 ATE288268T1 AT99960663T AT99960663T ATE288268T1 AT E288268 T1 ATE288268 T1 AT E288268T1 AT 99960663 T AT99960663 T AT 99960663T AT 99960663 T AT99960663 T AT 99960663T AT E288268 T1 ATE288268 T1 AT E288268T1
- Authority
- AT
- Austria
- Prior art keywords
- glp
- receptor
- peptide
- antagonists
- methods
- Prior art date
Links
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 title abstract 5
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000004913 activation Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 abstract 1
- 101710176384 Peptide 1 Proteins 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000003629 gastrointestinal hormone Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11173698P | 1998-12-10 | 1998-12-10 | |
| PCT/US1999/029065 WO2000033839A1 (en) | 1998-12-10 | 1999-12-08 | Non-peptide antagonists of glp-1 receptor and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE288268T1 true ATE288268T1 (de) | 2005-02-15 |
Family
ID=22340176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99960663T ATE288268T1 (de) | 1998-12-10 | 1999-12-08 | Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethoden |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6469021B1 (de) |
| EP (1) | EP1137413B1 (de) |
| JP (1) | JP2002531501A (de) |
| KR (1) | KR20010089563A (de) |
| AT (1) | ATE288268T1 (de) |
| AU (1) | AU758968B2 (de) |
| BR (1) | BR9916965A (de) |
| CA (1) | CA2350887A1 (de) |
| DE (1) | DE69923587T2 (de) |
| ES (1) | ES2233089T3 (de) |
| NZ (1) | NZ511698A (de) |
| PT (1) | PT1137413E (de) |
| WO (1) | WO2000033839A1 (de) |
| ZA (1) | ZA200104128B (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1292324A2 (de) | 2000-05-05 | 2003-03-19 | Novo Nordisk A/S | Neuropathien verursacht durch kritischen krankheiten |
| WO2002045712A1 (en) * | 2000-12-04 | 2002-06-13 | Biovitrum Ab | Novel method and use |
| AU2003203146A1 (en) * | 2002-02-07 | 2003-09-02 | Novo Nordisk A/S | Use of glp-1 compound for treatment of critically ill patients |
| US20030199445A1 (en) | 2002-02-07 | 2003-10-23 | Knudsen Lotte Bjerre | Use of GLP-1 compound for treatment of critically ill patients |
| AU2003206834B2 (en) | 2002-02-13 | 2006-10-19 | F. Hoffmann-La Roche Ag | Novel pyridine- and quinoline-derivatives |
| CN100503607C (zh) | 2003-06-02 | 2009-06-24 | 新疆华世丹药物研究有限责任公司 | 去氢骆驼蓬碱衍生物类化合物及其应用 |
| DK3456340T3 (da) | 2007-01-08 | 2022-03-21 | Univ Pennsylvania | Glp-1-receptorantagonist til brug ved behandling af medfødt hyperinsulisme |
| CA2700160A1 (en) * | 2007-09-20 | 2009-03-26 | D2E, Llc | Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use |
| WO2009067233A1 (en) * | 2007-11-20 | 2009-05-28 | Millennium Pharmaceuticals, Inc. | Beta carbolines and uses thereof |
| US10639354B2 (en) | 2015-05-22 | 2020-05-05 | The Bot Of The Leland Stanford Junior University | Treatment of hyperinsulinemic hypoglycemia with exendin (9-39) |
| US10653753B2 (en) | 2016-03-04 | 2020-05-19 | Eiger Biopharmaceuticals, Inc. | Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives |
| US11020484B2 (en) | 2016-11-21 | 2021-06-01 | Eiger Biopharmaceuticals, Inc. | Buffered formulations of exendin (9-39) |
| CN111362937B (zh) * | 2020-03-06 | 2021-06-22 | 贵州医科大学 | N-芳基-β-卡波林类衍生物及其用途 |
| CA3185634A1 (en) * | 2020-07-23 | 2022-01-27 | Merck Patent Gmbh | Tricyclic heterocycles |
| CA3195925A1 (en) * | 2020-10-30 | 2022-05-05 | Robin Elaine DUNCAN | Modulation of glucagon-like peptide 1 and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT823909E (pt) * | 1995-05-05 | 2002-12-31 | British Tech Group Inter Corpo | Nova quimica heterociclica |
-
1999
- 1999-12-08 NZ NZ511698A patent/NZ511698A/en unknown
- 1999-12-08 WO PCT/US1999/029065 patent/WO2000033839A1/en active IP Right Grant
- 1999-12-08 ES ES99960663T patent/ES2233089T3/es not_active Expired - Lifetime
- 1999-12-08 US US09/831,572 patent/US6469021B1/en not_active Expired - Fee Related
- 1999-12-08 EP EP99960663A patent/EP1137413B1/de not_active Expired - Lifetime
- 1999-12-08 PT PT99960663T patent/PT1137413E/pt unknown
- 1999-12-08 JP JP2000586331A patent/JP2002531501A/ja active Pending
- 1999-12-08 DE DE69923587T patent/DE69923587T2/de not_active Expired - Fee Related
- 1999-12-08 KR KR1020017007173A patent/KR20010089563A/ko not_active Application Discontinuation
- 1999-12-08 AT AT99960663T patent/ATE288268T1/de not_active IP Right Cessation
- 1999-12-08 AU AU17518/00A patent/AU758968B2/en not_active Ceased
- 1999-12-08 CA CA002350887A patent/CA2350887A1/en not_active Abandoned
- 1999-12-08 BR BR9916965-7A patent/BR9916965A/pt not_active IP Right Cessation
-
2001
- 2001-05-21 ZA ZA200104128A patent/ZA200104128B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2233089T3 (es) | 2005-06-01 |
| AU1751800A (en) | 2000-06-26 |
| EP1137413A4 (de) | 2002-06-26 |
| US6469021B1 (en) | 2002-10-22 |
| NZ511698A (en) | 2003-09-26 |
| JP2002531501A (ja) | 2002-09-24 |
| DE69923587D1 (de) | 2005-03-10 |
| EP1137413A2 (de) | 2001-10-04 |
| KR20010089563A (ko) | 2001-10-06 |
| PT1137413E (pt) | 2005-05-31 |
| AU758968B2 (en) | 2003-04-03 |
| BR9916965A (pt) | 2001-11-06 |
| DE69923587T2 (de) | 2005-06-23 |
| WO2000033839A1 (en) | 2000-06-15 |
| CA2350887A1 (en) | 2000-06-15 |
| ZA200104128B (en) | 2002-05-21 |
| WO2000033839B1 (en) | 2000-09-28 |
| EP1137413B1 (de) | 2005-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE288268T1 (de) | Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethoden | |
| MX9500072A (es) | Compuestos con propiedades de liberacion de la hormona del crecimiento. | |
| WO2004069158A3 (en) | Substituted pyrazoles, compositions containing such compounds and methods of use | |
| YU19903A (sh) | Novi receptor nukleinskih kiselina i polipeptida | |
| DE60005560D1 (de) | Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems | |
| YU22000A (sh) | Biciklični inhibitori kinaze | |
| EP0903349A3 (de) | CCR-3-Rezeptor-Antagonisten | |
| MXPA03004779A (es) | Nuevas benzazepinas y derivados heterociclicos relacionados, utiles como antagonistas del receptor de orexina. | |
| ES2000299A6 (es) | Procedimiento para la preparaciom de nuevos derivados de n-aralquil-piperinmetanol | |
| EP1773330A4 (de) | Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung | |
| IL139956A0 (en) | Conformationally constrained backbone cyclized somatostatin analogs | |
| MXPA02009773A (es) | Derivados de indolin-2-ona y su uso como ligandos de receptores de ocitocina. | |
| JO2359B1 (en) | Benzathene derivatives as agents for modulation of GABA A receptor | |
| ATE357917T1 (de) | Behandlung von dyskinesie durch mu-selektive opioidantagonisten | |
| EP1181555A4 (de) | Krebsbehandlung mit antagonisten des endothelinrezeptors | |
| GR950300029T1 (en) | Dna encoding a human serotonin receptor (5-ht4b)a nd uses thereof. | |
| MY127385A (en) | Arylsubstituted piperazines useful in the treatment of benign prostatic hyperlasia | |
| HK1026701A1 (en) | Heterocycles useful in the treatment of benign prostatic hyperplasia and intermediates thereof | |
| HK1064683A1 (en) | Receptor of the edb fibronectin domains (II) | |
| EP0960937A4 (de) | Neues semaphorin-gen: semaphorin y | |
| MXPA01002798A (es) | Antagonistas del receptor acoplado a la proteina g. | |
| NO20002408L (no) | 5-HT1F antagonister | |
| NZ513053A (en) | (1-phenacy-3-phenyl-3-piperidylethyl)piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same | |
| EP1346983A3 (de) | Phthalimido-arylpiperazine als alpha 1A Rezeptor Antagonisten nützlich zur Behandlung von gutartiger Prostatahyperplasie | |
| DK1235850T3 (da) | Umættede 14,15-cyclopropano-androstaner, fremgangsmåde til deres fremstilling og farmaceutiske præparater indeholdende disse forbindelser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1137413 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |